APA (7th ed.) Citation

G, C., B, R., SW, C., P, R., A, A., K, M. E., . . . C, J. (2024). Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. PloS one, 19(11), e0309778. https://doi.org/10.1371/journal.pone.0309778

Chicago Style (17th ed.) Citation

G, Cohen, et al. "Pembrolizumab 400 Mg Every 6 Weeks as First-line Therapy for Advanced Melanoma (KEYNOTE-555): Results from Cohort B of an Open-label, Phase 1 Study." PloS One 19, no. 11 (2024): e0309778. https://doi.org/10.1371/journal.pone.0309778.

MLA (9th ed.) Citation

G, Cohen, et al. "Pembrolizumab 400 Mg Every 6 Weeks as First-line Therapy for Advanced Melanoma (KEYNOTE-555): Results from Cohort B of an Open-label, Phase 1 Study." PloS One, vol. 19, no. 11, 2024, p. e0309778, https://doi.org/10.1371/journal.pone.0309778.